{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Greater than 2 grade 3 or 4 adverse events that are definitely, probably or possibly related to the pembrolizumab in the first cohort of 6 participants","groups":[{"description":"Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin\n\nPembrolizumab: 200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses\n\nRadiation Therapy: 70 Gy in 35 fractions over 7 weeks\n\nCisplatin: 100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.","id":"OG000","title":"Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"These are the first six participants that completed the study.","reportingStatus":"POSTED","timeFrame":"30 days following completion of treatment for the first 6 participants","title":"Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0","type":"PRIMARY","unitOfMeasure":"Participants"}